The ELNs signature we built was based on tumor sample data analysis; to further validate the expression of the prognostic genes constructing the ELNs signature, we analyzed the difference in seven RNAs (CDKN2B-AS1, H19, HOTTIP, LINC00643, MIR663AHG, TMEM236, and ZNF705A) between the normal samples and tumor samples. Here, SERTAD4BP is linked to neoplasm.